180 related articles for article (PubMed ID: 33038988)
1. CML - Not only BCR-ABL1 matters.
Rinke J; Hochhaus A; Ernst T
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101194. PubMed ID: 33038988
[TBL] [Abstract][Full Text] [Related]
2. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.
Kim T; Tyndel MS; Zhang Z; Ahn J; Choi S; Szardenings M; Lipton JH; Kim HJ; Kim Dong Hwan D
Leuk Res; 2017 Aug; 59():142-148. PubMed ID: 28667884
[TBL] [Abstract][Full Text] [Related]
3. Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.
Togasaki E; Takeda J; Yoshida K; Shiozawa Y; Takeuchi M; Oshima M; Saraya A; Iwama A; Yokote K; Sakaida E; Hirase C; Takeshita A; Imai K; Okumura H; Morishita Y; Usui N; Takahashi N; Fujisawa S; Shiraishi Y; Chiba K; Tanaka H; Kiyoi H; Ohnishi K; Ohtake S; Asou N; Kobayashi Y; Miyazaki Y; Miyano S; Ogawa S; Matsumura I; Nakaseko C; Naoe T
Blood Cancer J; 2017 Apr; 7(4):e559. PubMed ID: 28452984
[TBL] [Abstract][Full Text] [Related]
4. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
[TBL] [Abstract][Full Text] [Related]
6. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
[TBL] [Abstract][Full Text] [Related]
7. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
Schmidt M; Rinke J; Schäfer V; Schnittger S; Kohlmann A; Obstfelder E; Kunert C; Ziermann J; Winkelmann N; Eigendorff E; Haferlach T; Haferlach C; Hochhaus A; Ernst T
Leukemia; 2014 Dec; 28(12):2292-9. PubMed ID: 25212276
[TBL] [Abstract][Full Text] [Related]
8. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
9. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
10. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph
Peter B; Eisenwort G; Sadovnik I; Bauer K; Willmann M; Rülicke T; Berger D; Stefanzl G; Greiner G; Hoermann G; Keller A; Wolf D; Čulen M; Winter GE; Hoffmann T; Schiefer AI; Sperr WR; Zuber J; Mayer J; Valent P
Am J Hematol; 2022 Sep; 97(9):1215-1225. PubMed ID: 35794848
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
Soverini S; de Benedittis C; Mancini M; Martinelli G
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
[TBL] [Abstract][Full Text] [Related]
12. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
13. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
14. Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
Quintás-Cardama A; Cortes J
Blood; 2009 Feb; 113(8):1619-30. PubMed ID: 18827185
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
McCarron SL; O'Connor LM; Langabeer SE; Conneally E
Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
Patel AB; O'Hare T; Deininger MW
Hematol Oncol Clin North Am; 2017 Aug; 31(4):589-612. PubMed ID: 28673390
[TBL] [Abstract][Full Text] [Related]
17. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
20. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
